With Forty Sev­en co-founder at the helm, new biotech spin­out launch­es to tar­get mu­ta­tions po­ten­tial­ly linked to nu­mer­ous dis­eases

Mark Chao is go­ing back in­to biotech — and his new com­pa­ny, launched this morn­ing, is go­ing af­ter mys­te­ri­ous mu­ta­tions in the blood and how they im­pact dis­ease.

If the name seems fa­mil­iar, you might re­mem­ber Chao as one of the names be­hind Forty Sev­en, an im­muno-on­col­o­gy biotech that caught Gilead’s eye a few years back — and ul­ti­mate­ly its wal­let, when the biotech got bought out by the phar­ma for $4.9 bil­lion in 2020. Chao then came on board with Gilead as a VP of on­col­o­gy be­fore leav­ing to get on board with the new biotech.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN